PhaseBio Pharmaceuticals, Inc. (PHAS) financial statements (2021 and earlier)

Company profile

Business Address 1 GREAT VALLEY PARKWAY
MALVERN, PA 19355
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments748290526124
Cash and cash equivalents748290526124
Restricted cash and investments   00 
Receivables111100
Other undisclosed current assets413110
Total current assets:798395546325
Noncurrent Assets
Operating lease, right-of-use asset22  
Property, plant and equipment211000
Other noncurrent assets000000
Other undisclosed noncurrent assets  22 2
Total noncurrent assets:433203
TOTAL ASSETS:828697566327
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities644355
Accounts payable323222
Accrued liabilities310133
Employee-related liabilities 110  
Interest and dividends payable 000  
Debt2210 3
Other undisclosed current liabilities  00  
Total current liabilities:866458
Noncurrent Liabilities
Long-term debt and lease obligation1498784
Long-term debt, excluding current maturities1288784
Operating lease, liability22  
Liabilities, other than long-term debt000 0 
Deferred rent credit    0 
Other liabilities000   
Other undisclosed noncurrent liabilities  22 6
Total noncurrent liabilities:149109810
Total liabilities:231516121218
Temporary equity, carrying amount     126
Stockholders' equity
Stockholders' equity attributable to parent6071824451(116)
Common stock000000
Treasury stock, value(0)(0)(0)(0)(0)(0)
Additional paid in capital2222222211741742
Accumulated deficit(162)(151)(139)(130)(123)(118)
Other undisclosed stockholders' equity     (0)
Total stockholders' equity:6071824451(116)
TOTAL LIABILITIES AND EQUITY:828697566327

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
Gross profit:101100
Operating expenses(12)(12)(10)(8)(8)(5)
Operating loss:(11)(12)(9)(7)(8)(5)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(0)0003(3)
Interest and debt expense(0)(0)(0)(0)(0)(1)
Loss before gain (loss) on sale of properties:(12)(12)(9)(8)(5)(9)
Other undisclosed net income0  00 
Net loss:(11)(12)(9)(7)(5)(9)
Other undisclosed net income attributable to parent 00  1
Net loss available to common stockholders, diluted:(11)(11)(9)(7)(5)(8)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
Net loss:(11)(12)(9)(7)(5)(9)
Comprehensive loss, net of tax, attributable to parent:(11)(12)(9)(7)(5)(9)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: